<!DOCTYPE html>
<html>
<head>
<link href="https://fonts.googleapis.com/css2?family=Oxanium&display=swap" rel="stylesheet">
<style>

body {
    font-family: 'Oxanium', cursive;
}

span {color:#f8df92;}
p {color:red;font-family:'Oxanium', cursive;}

.main {
  width: 100%;
  height: 100%;
  overflow-y: scroll; /* Add the ability to scroll */
}

/* Hide scrollbar for Chrome, Safari and Opera */
.main::-webkit-scrollbar {
    display: none;
}

/* Hide scrollbar for IE, Edge and Firefox */
.main {
  -ms-overflow-style: none;  /* IE and Edge */
  scrollbar-width: none;  /* Firefox */
}

.content {
  width: auto;
  height: 365px;
  font-size:7pt;
  font-family:'Oxanium', cursive;
  color:#f8df92;
  background-color:transparent;
  line-height:1.38;
  margin-top:0pt;
  margin-bottom:0pt;
  padding-right:5pt;
  /* border-right: 2px solid rgba(255, 233, 185, 0.5); */
  overflow-y: scroll; /* Add the ability to scroll */
}

.author {
  font-weight:700;
  font-style:normal;
  font-variant:normal;
  // text-decoration:underline;
  -webkit-text-decoration-skip:none;
  text-decoration-skip-ink:none;
  vertical-align:baseline;
  white-space:pre;
  white-space:pre-wrap;"
}

.article {
  font-weight:400;
  font-style:normal;
  font-variant:normal;
  text-decoration:none;
  vertical-align:baseline;
  white-space:pre;
  white-space:pre-wrap;
}

/* width */
::-webkit-scrollbar {
  width: 2px;
}

/* Track */
::-webkit-scrollbar-track {
  border-radius: 0px;
}
 
/* Handle */
::-webkit-scrollbar-thumb {
  background: #f8df92; 
  border-radius: 0px;
}

/* Handle on hover */
::-webkit-scrollbar-thumb:hover {
  background: #f8df92; 
}

</style>
</head>
<body>
<div class="main">
<p style="line-height:1.38;margin-top:0pt;margin-bottom:0pt;color:#f8df92;">
	<span style="font-size:15pt;font-weight:700;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;">IMPORTANT SAFETY INFORMATION</span>
</p>


<div class="content">
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Indications</span>
			<span class="article"></span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME). </span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Contraindications</span>
			<span class="article"></span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">VABYSMO is contraindicated in patients with ocular or periocular inflammation, in patients with active intraocular inflammation, and in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO. </span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Warnings and Precautions</span>

				<ul style="margin-top:0; padding-top:0;">
					<li>Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management. </li>
					<li>Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.</li>
					<li>There is a potential risk of arterial thromboembolic events (ATEs) associated with VEGF inhibition. </li>
				</ul>

		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author">Adverse Reactions</span>
			<span class="article"></span>
		</a>
	</p>
	<p>
		<a target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">The most common adverse reaction (â‰¥5%) reported in patients receiving VABYSMO was conjunctival hemorrhage (7%).</span>
		</a>
	</p>
	<p>
		<a href="https://www.fda.gov/medwatch" target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.</span>
		</a>
	</p>
	<p>
		<a href="https://www.gene.com/download/pdf/vabysmo_prescribing.pdf" target="_blank" style="text-decoration:none;">
			<span class="author"></span>
			<span class="article">Please see additional Important Safety Information in the full VABYSMO Prescribing Information.</span>
		</a>
	</p>

</div>
</div>
</body>
</html>